

COMPANY PROFILE

Asensus Surgical, Inc. is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes.

Based on the foundation and our experience with the Senhance® Surgical System, the company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its digital surgery solution. These systems will be powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare.

COMPANY SNAPSHOT

Stock Symbol: ASXC

Stock Exchange: NYSE American

Headquarters: Research Triangle Park, NC

- Active sites in **14 countries across the US, EU, and Asia**
- **FDA, CE Mark, Roszdravnadzor, and PMDA approved**
- **>14,000 surgical procedures performed to date**
- **200+** global employees
- **>100** surgeon users
- **325+** patents and pending applications

DIGITIZING MINIMALLY INVASIVE SURGERY (LAPAROSCOPY)

SENHANCE SURGICAL SYSTEM

First and only Digital Laparoscopy surgical robotic platform globally.



SURGEON BENEFIT

- Enhanced control during surgery with surgeon eye-sensing camera control & 3DHD vision
- Enhanced precision through tremor filtrations and robotic stabilization
- Enhanced focus during surgery through optimized ergonomics and the sense of touch (haptics) for the first time in robotic surgery

PERFORMANCE-GUIDED SURGERY

First surgical robotic system with Augmented Intelligence capabilities.



HOSPITAL BENEFIT

- Per-procedure cost similar to traditional laparoscopy
- Highly configurable, allowing hospitals to use existing operating room infrastructure

PATIENT BENEFIT

- Smallest instruments offered in robotics leading to >86% smaller incisions vs traditional robotic surgery

2024 STRATEGIC PRIORITIES

MARKET DEVELOPMENT

Building awareness and demonstrating clinical and economic value.

CLINICAL VALIDATION


Developing clinical evidence to support the value propositions of Senhance.

PORTFOLIO EXPANSION

Broadening the applicability of Senhance by adding new indications, features, and instruments.

NEXT GENERATION SOLUTIONS

The LUNA Surgical System is the next generation digital surgery platform, currently under development and not currently available for use.



MARKET OPPORTUNITY

The abdominal robotic surgery market currently has a very low penetration into the surgical market and is projected to grow at a **double digit CAGR over the foreseeable future.**¹

MILESTONES COMPLETED

LUNA SYSTEMS

- ✓ Integrated System testing - Q4 2023
- ✓ Finalization of Contract Manufacturing Partner - Q4 2023
- ✓ Pre-Clinical Evaluation - Q4 2023

Updated ISU Platform for LUNA

- ✓ Strategic Partnership with Graphics Hardware Provider - Q3 2023

Senhance System Placements

- ✓ 8 Senhance placements in 2023

ISU - THE WORLD'S FIRST AUGMENTED INTELLIGENCE SYSTEM CLEARED BY THE FDA

The ISU, or Intelligent Surgical Unit, is the missing piece in the OR, and empowers surgeons to be more effective and more efficient, regardless of their skill level.

The ISU captures and analyzes laparoscopic video feeds during surgery. It provides actionable, real-time information to surgeons when it matters most - during the actual surgical procedure.



FORWARD-LOOKING STATEMENT

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. The information contained herein is not a prospectus and does not constitute an offer to sell nor a solicitation of an offer to buy any security.

1. Goldman Sachs Global Investment Research, Healthcare Cost and Utilization Project (HCUP), Global Market Insights, Mordor Intelligence, company analysis



Learn more at [Asensus.com](https://www.asensus.com)

Asensus Surgical, Inc. | 1 TW Alexander Drive | Durham, NC 27703 USA | +1 919-765-8400